The firm is investigating viability of voriconazole inhalation powder, intended to treat and prevent invasive pulmonary aspergillosis in asthma patients.
The CPhI Worldwide exhibitor will show Syloid XDP, a silica carrier designed to convert liquid, waxy, or oily active ingredients into free-flowing powders.
The virtual event (scheduled June 22-24) will feature presentations from Bayer, Merck, GSK, Novartis, Takeda, FDA, WHO, and other notable organizations.
The head of small-molecule business for the pharma solutions specialist talks about obstacles, and how companies can work to clear them for future success.
The company has increased capabilities at its Bend, Oregon location, including its SimpliFiH Solutions first-in-human services for small-molecule drugs.
The drug delivery platform company is exploring the viability of remdesivir and other potential treatments for the virus using its DehydraTECH technology.
